Health Care [ 3/12 ] | Biotechnology [ 26/73 ]
NASDAQ | Common Stock
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform.
The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer.
It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.
The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV.
HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -1.22 Decreased by -1.21 K% | -1.04 Decreased by -17.23% |
| Mar 20, 25 | -0.74 Decreased by -236.36% | -0.69 Decreased by -7.25% |
| Nov 7, 24 | -1.10 Decreased by -547.06% | -1.28 Increased by +14.06% |
| Aug 8, 24 | -1.52 Decreased by -590.91% | -1.25 Decreased by -21.60% |
| May 9, 24 | 0.11 Increased by +140.74% | -0.10 Increased by +210.00% |
| Mar 22, 24 | -0.22 Decreased by -29.41% | -0.19 Decreased by -15.79% |
| Nov 9, 23 | -0.17 Increased by +32.00% | -0.21 Increased by +19.05% |
| Aug 10, 23 | -0.22 Increased by +4.35% | -0.21 Decreased by -4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.00 M Decreased by -94.52% | -15.43 M Decreased by -207.26% | Decreased by -769.81% Decreased by -2.06 K% |
| Dec 31, 24 | 1.35 M Decreased by -81.72% | -24.95 M Decreased by -0.53% | Decreased by -1.84 K% Decreased by -449.96% |
| Sep 30, 24 | 4.70 M Decreased by -31.51% | -13.84 M Increased by +27.40% | Decreased by -294.30% Decreased by -6.00% |
| Jun 30, 24 | 1.29 M Decreased by -51.85% | -19.09 M Decreased by -5.99% | Decreased by -1.48 K% Decreased by -120.11% |
| Mar 31, 24 | 36.60 M Increased by +1.05 K% | 14.38 M Increased by +173.08% | Increased by +39.30% Increased by +106.34% |
| Dec 31, 23 | 7.41 M Decreased by -5.38% | -24.82 M Decreased by -101.59% | Decreased by -335.06% Decreased by -113.05% |
| Sep 30, 23 | 6.87 M Increased by +207.94% | -19.07 M Decreased by -4.30% | Decreased by -277.65% Increased by +66.13% |
| Jun 30, 23 | 2.68 M Decreased by -2.44% | -18.02 M Decreased by -10.15% | Decreased by -672.49% Decreased by -12.90% |